-

908 Devices to Participate in the Cowen 43rd Annual Healthcare Conference

BOSTON--(BUSINESS WIRE)--908 Devices Inc., (Nasdaq: MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the upcoming Cowen 43rd Annual Healthcare Conference in Boston, MA.

908 Devices’ management is scheduled to host a fireside chat on Wednesday, March 8 at 9:50 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.908devices.com.

About 908 Devices

908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma/biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic sampling and separations, software automation, and machine learning.

Contacts

Media
Barbara Russo
brusso@908devices.com

Investor
Carrie Mendivil
IR@908devices.com

908 Devices Inc.

NASDAQ:MASS

Release Versions

Contacts

Media
Barbara Russo
brusso@908devices.com

Investor
Carrie Mendivil
IR@908devices.com

More News From 908 Devices Inc.

908 Devices Receives $1.7M Order from the Ministry of Health of Ukraine for its Handheld Mass Spec Device

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer in purpose-built handheld devices for chemical analysis, announces that it has received a $1.7 million order from the Ministry of Health of Ukraine for its MX908 handheld mass spectrometry device with Aero module for priority shipment in the first quarter 2025. The devices will be part of an environmental testing kit in a post-war environment and will be used primarily to detect and identify trace substances of hazardous materi...

908 Devices Announces Strategic Transformation and Reports Fourth Quarter and Full Year 2024 Financial Results

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter and full year ended December 31, 2024. Strategic Transformation Realized 908 Devices cements its unique position as a market-leading provider of analytical tools for tackling critical public health and safety crises through the divestiture of its bioprocessing desktop assets to Repligen Corporation. This transac...

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

WALTHAM, Mass., & BOSTON--(BUSINESS WIRE)--Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (Nasdaq: MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices’ desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on the growth of its newly expanded handheld device...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.